Cannabis & Capital analysis
California cannabis sales opened 2026 below both comparison points
California retailers reported $956.7 million in Q1 cannabis sales, down from both Q1 2025 and Q4 2025. The modest decline matters because it narrows the margin for optimistic growth assumptions.
The signal
California retailers reported $956.7 million in cannabis sales for Q1 2026. That was 2.0% below Q1 2025 and 2.8% below Q4 2025.
Neither comparison is dramatic on its own. Taken together, however, they make one point difficult to ignore: California entered 2026 without top-line momentum in the reported retail market. The data does not explain why sales moved, but it does challenge plans that assume growth will do the heavy lifting.
The numbers
- Reported cannabis sales: $956.7 million in Q1 2026
- Year-over-year change: -2.0% compared with Q1 2025
- Quarter-over-quarter change: -2.8% compared with Q4 2025
- Total cannabis tax reported: $247.9 million across the available excise, sales, and cultivation tax fields
Why it matters
For operators, a market that is modestly lower against both comparison periods leaves less room for weak inventory turns, broad discounting, or expansion plans built on automatic category growth. The statewide result is not a verdict on any individual company, but it raises the value of knowing exactly where margin and repeat demand are coming from.
For investors and lenders, the same result puts more weight on cash generation, balance-sheet durability, and projections that still work under flat or mildly lower sales. A forecast can be ambitious, but Q1 offers a useful reason to test what happens when the market does not provide a tailwind.
For vendors and advisors, the opportunity is similarly specific: tools that improve retention, working-capital visibility, compliance efficiency, or unit economics become easier to evaluate when the customer cannot rely on broad market expansion.
These are implications, not causes established by the CDTFA data.
What to watch
The next useful evidence will be the Q2 2026 release and any revisions to Q1. A rebound would support the view that the opening quarter was temporary softness. Another comparable decline would make the question of a broader pattern harder to dismiss.
Reported figures may be revised, and the quarterly comparisons are not seasonally adjusted. Product mix, pricing, store openings and closures, illicit-market activity, and reporting behavior may all matter, but this dataset does not isolate their effects.
Methodology
Cannabis & Capital compared CDTFA quarterly cannabis sales fields for Q1 2026 with the immediately preceding quarter and the same quarter one year earlier. Tax revenue is shown from the excise, sales, and cultivation fields available in the source record. The work is original Cannabis & Capital analysis of public data; it does not establish causation or provide investment, legal, or compliance advice.